StocksFundsScreenerSectorsWatchlists
BHC

BHC - Bausch Health Cos Inc Stock Price, Fair Value and News

8.64USD+0.04 (+0.47%)Delayed as of 19 Apr 2024, 11:03 am ET

Market Summary

BHC
USD8.64+0.04
Delayedas of 19 Apr 2024, 11:03 am
0.47%

BHC Stock Price

View Fullscreen

BHC RSI Chart

BHC Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-5.31

Price/Sales (Trailing)

0.36

EV/EBITDA

10.96

Price/Free Cashflow

3.85

BHC Price/Sales (Trailing)

BHC Profitability

EBT Margin

-4.45%

Return on Equity

721.95%

Return on Assets

-2.16%

Free Cashflow Yield

26%

BHC Fundamentals

BHC Revenue

Revenue (TTM)

8.8B

Rev. Growth (Yr)

9.8%

Rev. Growth (Qtr)

7.6%

BHC Earnings

Earnings (TTM)

-592.0M

Earnings Growth (Yr)

90.49%

Earnings Growth (Qtr)

89.68%

Breaking Down BHC Revenue

52 Week Range

8.75
(Low)(High)

Last 7 days

-4.1%

Last 30 days

-9.8%

Last 90 days

5.5%

Trailing 12 Months

14.2%

How does BHC drawdown profile look like?

BHC Financial Health

Current Ratio

1.3

Debt/Equity

-267.54

Debt/Cashflow

0.05

BHC Investor Care

Dividend Yield

15.04%

Dividend/Share (TTM)

1.28

Shares Dilution (1Y)

0.93%

Diluted EPS (TTM)

-1.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20238.2B8.3B8.5B8.8B
20228.3B8.2B8.1B8.1B
20218.0B8.5B8.5B8.4B
20208.6B8.1B8.0B8.0B
20198.4B8.4B8.5B8.6B
20188.6B8.5B8.4B8.4B
20179.4B9.2B9.0B8.7B
201610.6B10.3B10.0B9.7B
20158.5B9.2B9.9B10.4B
20146.6B7.5B8.0B8.2B
20133.7B4.0B4.6B5.8B
20122.7B2.9B3.2B3.5B
20111.5B1.9B2.3B2.4B
2010866.7M912.0M907.7M1.2B
20090778.3M799.3M820.4M
2008000757.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bausch Health Cos Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 29, 2024
robertson russel c
acquired
31,246
10.61
2,945
-
Mar 29, 2024
wechsler amy b
acquired
6,864
10.61
647
-
Mar 29, 2024
paulson john
acquired
62,492
10.61
5,890
-
Mar 29, 2024
icahn brett
acquired
33,124
10.61
3,122
-
Mar 04, 2024
carson seana
sold
-61,867
9.8
-6,313
evp, general counsel
Mar 01, 2024
appio thomas
sold (taxes)
-1,156,950
9.89
-116,982
chief executive officer
Mar 01, 2024
carson seana
sold (taxes)
-239,763
9.89
-24,243
evp, general counsel
Mar 01, 2024
barresi john s
sold (taxes)
-31,529
9.89
-3,188
svp, controller & cao
Feb 29, 2024
carson seana
acquired
-
-
147,536
evp, general counsel
Feb 29, 2024
barresi john s
acquired
-
-
39,126
svp, controller & cao

1–10 of 50

Which funds bought or sold BHC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
Coston, McIsaac & Partners
unchanged
-
1,000
2,000
-%
Apr 16, 2024
Financial Management Professionals, Inc.
unchanged
-
1,000
7,000
-%
Apr 16, 2024
Viewpoint Capital Management LLC
unchanged
-
48,951
200,529
0.13%
Apr 16, 2024
VOISARD ASSET MANAGEMENT GROUP, INC.
unchanged
-
1,295
5,305
-%
Apr 16, 2024
MCF Advisors LLC
unchanged
-
96.00
393
-%
Apr 16, 2024
TOTH FINANCIAL ADVISORY CORP
unchanged
-
389
1,592
-%
Apr 15, 2024
DGS Capital Management, LLC
sold off
-100
-89,640
-
-%
Apr 15, 2024
THOMPSON INVESTMENT MANAGEMENT, INC.
reduced
-3.64
482,334
2,237,590
0.34%
Apr 12, 2024
IMC-Chicago, LLC
new
-
593,937
593,937
-%
Apr 12, 2024
Ausdal Financial Partners, Inc.
sold off
-100
-84,210
-
-%

1–10 of 40

Are Funds Buying or Selling BHC?

Are funds buying BHC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BHC
No. of Funds

Unveiling Bausch Health Cos Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
goldentree asset management lp
7.6%
27,644,959
SC 13G/A
Feb 07, 2024
icahn carl c
3.95%
14,423,595
SC 13D/A
Feb 14, 2023
nomura holdings inc
3.6%
13,030,352
SC 13G/A
Feb 13, 2023
goldentree asset management lp
5.4%
19,421,054
SC 13G
May 13, 2022
va partners i, llc
4.0%
14,430,901
SC 13D/A
Feb 14, 2022
nomura holdings inc
5.4%
19,515,079
SC 13G
Dec 13, 2021
glenview capital management, llc
4.75%
17,078,657
SC 13D/A
Jun 21, 2021
va partners i, llc
5.0%
17,941,603
SC 13D/A
Apr 23, 2021
meruelo alex
5.51%
19,604,777
SC 13G
Mar 16, 2021
icahn carl c
3.98%
14,169,189
SC 13D/A

Recent SEC filings of Bausch Health Cos Inc

View All Filings
Date Filed Form Type Document
Apr 04, 2024
DEFA14A
DEFA14A
Apr 04, 2024
DEF 14A
DEF 14A
Apr 04, 2024
ARS
ARS
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading

Peers (Alternatives to Bausch Health Cos Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
351.1B
85.2B
-6.70% -10.33%
9.99
4.12
6.46% 95.94%
317.1B
60.1B
2.45% 9.70%
868.73
5.27
1.40% -97.49%
143.3B
46.5B
-8.14% -36.93%
-103.22
3.08
42.59% -114.62%
140.8B
28.2B
-3.32% 6.70%
20.96
4.99
7.09% 2.52%
82.4B
27.1B
-9.93% -21.39%
14.54
3.04
-0.60% 23.36%
14.3B
15.8B
-4.27% 50.53%
-24.85
0.9
6.17% 76.47%
MID-CAP
4.1B
4.7B
-0.96% -17.31%
-319.48
0.87
4.58% 90.97%
4.0B
1.7B
-14.12% -18.81%
11.16
2.39
49.61% 324.78%
3.1B
8.8B
-9.85% 14.21%
-5.31
0.36
7.79% -163.11%
1.9B
644.4M
-13.30% -10.60%
13.51
2.88
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-9.90% -28.22%
-3.8
1.8
24.65% 80.36%
21.7M
1.3M
-17.90% -49.05%
-2.11
16.65
-98.14% -109.18%
17.6M
-
-9.57% 32.48%
-0.96
0.22
2882.68% -138.52%
2.5M
19.6M
-30.19% -94.45%
-0.18
0.13
80.00% 43.08%
472.0K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Bausch Health Cos Inc News

Latest updates
The Globe and Mail18 hours ago
Yahoo Finance01 Apr 202407:00 am

Bausch Health Cos Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue7.6%2,408,000,0002,238,000,0002,167,000,0001,944,000,0002,193,000,0002,046,000,0001,967,000,0001,918,000,0002,196,000,0002,111,000,0002,100,000,0002,027,000,0002,213,000,0002,138,000,0001,664,000,0002,012,000,0002,224,000,0002,209,000,0002,152,000,0002,016,000,0002,121,000,000
Costs and Expenses-8.0%2,046,000,0002,224,000,0001,755,000,0001,769,000,0002,429,000,0001,802,000,0001,806,000,0001,633,000,0001,829,000,0001,537,000,0002,370,000,0002,248,000,0002,218,000,0001,678,000,0001,691,000,0001,764,000,0003,300,000,0001,880,000,0001,895,000,0001,729,000,0002,096,000,000
  S&GA Expenses7.1%766,000,000715,000,000711,000,000725,000,000666,000,000661,000,000676,000,000622,000,000680,000,000653,000,000685,000,000606,000,000636,000,000572,000,000526,000,000633,000,000668,000,000648,000,000651,000,000587,000,000626,000,000
EBITDA Margin17.6%0.250.210.320.320.340.390.360.290.230.190.190.24---------
Interest Expenses7.1%363,000,000339,000,000319,000,000307,000,000307,000,000385,000,000410,000,000362,000,000343,000,000351,000,000364,000,000368,000,000379,000,000374,000,000385,000,000396,000,000391,000,000406,000,000409,000,000406,000,000-
Income Taxes-28.6%40,000,00056,000,00052,000,00073,000,00053,000,00036,000,00010,000,000-16,000,000-51,000,00025,000,000-77,000,00016,000,000-242,000,0005,000,000-112,000,000-26,000,00047,000,000-18,000,000-9,000,000-74,000,000-84,000,000
Earnings Before Taxes97.9%-7,000,000-326,000,00079,000,000-136,000,000-357,000,000439,000,000-129,000,000-82,000,00021,000,000216,000,000-670,000,000-591,000,000-394,000,00075,000,000-437,000,000-178,000,000-1,470,000,000-66,000,000-179,000,000-122,000,000-426,000,000
EBT Margin48.6%-0.04-0.090.00-0.02-0.020.030.00-0.06-0.12-0.17-0.19-0.17---------
Net Income89.7%-39,000,000-378,000,00026,000,000-201,000,000-410,000,000399,000,000-145,000,000-69,000,00069,000,000188,000,000-595,000,000-610,000,000-153,000,00071,000,000-326,000,000-152,000,000-1,516,000,000-49,000,000-171,000,000-52,000,000-344,000,000
Net Income Margin40.0%-0.07-0.11-0.02-0.04-0.030.030.01-0.05-0.11-0.14-0.15-0.13---------
Free Cashflow21.7%292,000,000240,000,000178,000,000107,000,000409,000,000-1,317,000,00071,000,000-109,000,000-54,000,000501,000,000333,000,000377,000,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.1%27,35027,06425,50325,44525,68626,29828,17129,09029,20229,25230,04230,19731,19931,56231,39632,63033,86331,66732,35432,55132,492
  Current Assets10.9%5,5965,0484,4614,2374,2474,0105,4175,8365,6075,3245,4505,3925,3425,6715,2785,5046,9694,3054,4674,2754,211
    Cash Equivalents24.6%9477605795185644866591,2495826906426791,8169778969123,244825878782721
  Inventory21.4%1,5441,2721,2401,2221,0901,0561,0731,0459931,0581,0861,0761,0941,2241,2261,1241,1071,1001,0601,012934
  Net PPE7.8%1,7071,5841,5991,5961,6001,5071,5451,5791,5981,5841,5901,5561,5671,5501,4961,4501,4661,3901,3721,3411,353
  Goodwill48521.7%11,18323.0011,62811,57911,54712,04412,26612,42712,45712,47712,52712,48513,04413,16013,08413,03413,12613,05213,16013,12113,142
Liabilities0.5%27,43227,29925,23225,30025,42625,86527,91829,23129,23629,38730,65330,32130,59430,90730,85031,07532,72729,10729,66629,77229,677
  Current Liabilities1.8%4,3024,2243,9673,9233,9413,8314,9974,7745,1985,4375,5174,8984,9134,7324,7184,8866,2483,7353,7053,9413,836
  Long Term Debt0.2%21,93821,89420,10820,20720,33420,80421,66423,16822,65422,35823,43923,73823,92524,34324,35724,42424,66123,46624,02323,92424,077
    LT Debt, Current-16.0%450536444446432411150-------1.004.001,23410056.00257228
    LT Debt, Non Current0.2%21,93821,89420,10820,20720,33420,80421,66423,16822,65422,35823,43923,73823,92524,34324,35724,42424,66123,46624,02323,92424,077
Shareholder's Equity-Infinity%-82.00-271145260433253--34.00---6056555467901,1362,5602,6882,7792,815
  Retained Earnings-0.4%-9,778-9,739-9,361-9,387-9,186-8,776-9,175-9,030-8,961-9,030-9,218-8,623-8,013-7,860-7,931-7,605-7,452-5,936-5,887-5,716-5,664
  Additional Paid-In Capital12.6%214190188171159129104415462437413393454435411396429406384374413
Shares Outstanding0.1%365365364364362363362361359359358357---------
Minority Interest-0.5%94094593494595295894675.0072.0069.0076.0073.0070.0068.0072.0071.0073.0078.0087.0086.0082.00
Float---2,419---2,507---8,714---5,665---7,881--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations38.3%390282206154475-1,263123-63.0024.00564395443394256200261234515339413319
  Share Based Compensation0%29.0029.0033.0041.0035.0033.0026.0032.0033.0033.0031.0031.0024.0027.0027.0027.0025.0026.0027.0024.0022.00
Cashflow From Investing92.2%-148-1,889-30.00-78.00-136-53.00-58.00-56.00-80.00588-43.00-56.00-84.00-70.00-67.00-40.00-85.00-73.00-58.00-203-62.00
Cashflow From Financing-104.4%-79.001,816-120-142-276-36.00-630468275-1,157-388-243-503-117-153-1,5212,255-474-188-150-502

BHC Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues   
Revenues$ 8,757$ 8,124$ 8,434
Expenses   
Selling, general and administrative2,9172,6252,624
Research and development604529465
Amortization of intangible assets1,0771,2151,375
Goodwill impairments493824469
Asset impairments, including loss on assets held for sale5415234
Restructuring, integration, separation and IPO costs626350
Other expense, net2835373
Total Expenses7,7947,6707,984
Operating income963454450
Interest income26147
Interest expense(1,328)(1,464)(1,426)
Gain (loss) on extinguishment of debt1875(62)
Foreign exchange and other(52)(8)7
Loss before income taxes(390)(129)(1,024)
(Provision for) benefit from income taxes(221)(83)87
Net loss(611)(212)(937)
Net loss (income) attributable to noncontrolling interest19(13)(11)
Net loss attributable to Bausch Health Companies Inc.$ (592)$ (225)$ (948)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)$ (1.62)$ (0.62)$ (2.64)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)$ (1.62)$ (0.62)$ (2.64)
Basic weighted-average common shares (in shares)364,900362,000358,900
Diluted weighted-average common shares (in shares)364,900362,000358,900
Product sales   
Revenues   
Revenues$ 8,663$ 8,025$ 8,328
Expenses   
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues2,5192,3162,350
Other revenues   
Revenues   
Revenues9499106
Expenses   
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues$ 40$ 48$ 44

BHC Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 947$ 564
Restricted cash and other settlement deposits1527
Trade receivables, net1,9981,790
Inventories, net1,5441,090
Prepaid expenses and other current assets1,092776
Total current assets5,5964,247
Property, plant and equipment, net1,7071,600
Intangible assets, net6,4565,800
Goodwill11,18311,547
Deferred tax assets, net2,1012,166
Other non-current assets307326
Total assets27,35025,686
Current liabilities:  
Accounts payable719521
Accrued and other current liabilities3,1332,988
Current portion of long-term debt450432
Total current liabilities4,3023,941
Acquisition-related contingent consideration253208
Non-current portion of long-term debt21,93820,334
Deferred tax liabilities, net163202
Other non-current liabilities776741
Total liabilities27,43225,426
Commitments and contingencies (Notes 20 and 21)
(Deficit) Equity  
Common shares, no par value, unlimited shares authorized, 365,238,917 and 361,898,846 issued and outstanding at December 31, 2023 and 2022, respectively10,42310,391
Additional paid-in capital214159
Accumulated deficit(9,778)(9,186)
Accumulated other comprehensive loss(1,881)(2,056)
Total Bausch Health Companies Inc. shareholders’ deficit(1,022)(692)
Noncontrolling interest940952
Total (deficit) equity(82)260
Total liabilities and (deficit) equity$ 27,350$ 25,686
BHC
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.
 CEO
 WEBSITEbauschhealth.com
 INDUSTRYPharmaceuticals
 EMPLOYEES19900

Bausch Health Cos Inc Frequently Asked Questions


What is the ticker symbol for Bausch Health Cos Inc? What does BHC stand for in stocks?

BHC is the stock ticker symbol of Bausch Health Cos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch Health Cos Inc (BHC)?

As of Thu Apr 18 2024, market cap of Bausch Health Cos Inc is 3.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BHC stock?

You can check BHC's fair value in chart for subscribers.

What is the fair value of BHC stock?

You can check BHC's fair value in chart for subscribers. The fair value of Bausch Health Cos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bausch Health Cos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BHC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bausch Health Cos Inc a good stock to buy?

The fair value guage provides a quick view whether BHC is over valued or under valued. Whether Bausch Health Cos Inc is cheap or expensive depends on the assumptions which impact Bausch Health Cos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BHC.

What is Bausch Health Cos Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, BHC's PE ratio (Price to Earnings) is -5.31 and Price to Sales (PS) ratio is 0.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BHC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bausch Health Cos Inc's stock?

In the past 10 years, Bausch Health Cos Inc has provided -0.235 (multiply by 100 for percentage) rate of return.